🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against superbug strains of the pathogen, according to health experts.

An International Health Concern

The sexually transmitted infection are on the rise around the world, with estimates suggesting over 82 million new cases each year. Particularly high rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, the spread of superbugs and the very limited available drugs presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The WHO has designated it as a "high-priority threat". Ongoing monitoring found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment emerged from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Research Study Outcomes and Worldwide Availability

According to data released by a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses two antibiotics. The research enrolled nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in many regions with limited resources.

Medical professionals directly involved have shared positive views. The availability of a one-pill regimen of this kind is described as a "revolutionary step" for managing the epidemic. This is deemed essential to reduce the burden of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.